Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The ...

The policy has been outlined in an editorial in the New England Journal of Medicine (NEJM) by FDA Commissioner Marty Makary ...